ClinicalTrials.govpublic full text
A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
neoplasms, lung, carcinoma, non-small cell lung, drug therapy, genes, egfr, mutation analysis, first-line, second-line, targeted therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 968806
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.